<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Miskulin, Dana C.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Ergocalciferol Supplementation in Patients Undergoing Hemodialysis is Safe but without Benefit</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-01-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">11-12</style></pages><abstract><style  face="normal" font="default" size="100%">Vitamin D deficiency has been linked to cardiovascular events and mortality, infection, and autoimmune disorders. Deficiency of 25-hydroxyvitamin D [25(OH)D] &lt;30 ng/mL occurs in about 80% of patients undergoing dialysis. The double-blind, placebo-controlled Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients [NCT01395823] trial investigated the safety and effects of dosing on dialysis patients, as discussed in this article.</style></abstract><number><style face="normal" font="default" size="100%">49</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>